PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument

PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With
Mortara Instrument

BOSTON, Nov. 9 /PRNewswire-FirstCall/ -- PAREXEL International Corporation
(Nasdaq: PRXL), a leading global biopharmaceutical services provider, today
announced that it has enhanced its cardiac safety capabilities for early phase
clinical development through an alliance with Mortara Instrument, Inc., which
manufactures and distributes electrocardiogram (ECG) devices and related
technology worldwide. PAREXEL is using Mortara Instrument's Surveyor Telemetry
Central System to supplement its state-of-the-art ECG equipment to support
biopharmaceutical companies in improving cardiac safety assessment of new
compounds.

Designed to address the growing ECG requirements of early phase cardiac safety
studies, Mortara's Surveyor Telemetry Central System allows PAREXEL to acquire
and store continuous, diagnostic 12-lead ECG data, which is wirelessly
transmitted from devices worn by clinical trial participants. The Mortara
solution, which has been fully implemented and validated in PAREXEL's early
phase clinical unit located in Baltimore, Maryland in the United States,
provides live monitoring and automated acquisition and recording of ECGs for
analysis and transmission to core labs. This solution extends the technology
capabilities for ECG and QT/QTc studies conducted in PAREXEL's other early
phase units worldwide, including sites located in Los Angeles, California in
the United States as well as in London, United Kingdom; Berlin, Germany; and
Bloemfontein, George, and Port Elizabeth, South Africa.

"With growing regulatory requirements, cardiac safety studies have become
increasingly important within a clinical development program. We help
biopharmaceutical companies gather cardiac safety data early in the
development cycle for maximum efficiency," said Michelle Middle, MB ChB,
Corporate Vice President and Worldwide Head of Early Phase, PAREXEL
International. "Our alliance with Mortara Instrument provides customers with
improved automation in the acquisition and reporting of ECG data for greater
data accuracy and faster, better decision making. This relationship represents
our commitment to providing comprehensive early phase cardiovascular expertise
and capabilities, such as intensive ECG and thorough QT/QTc studies, supported
by enabling technologies."

Each of PAREXEL's early phase clinical units has state-of-the-art equipment
and performs cardiac studies according to international guidelines. The units
are equipped with telemetric and bedside monitoring as well as ECG equipment
for continuous registration. PAREXEL's early phase experts provide
top-quality, evidence-supported readings of clinical cardiovascular data and
work in collaboration with ECG core labs. PAREXEL's early phase services
include a wide range of cardiovascular-related capabilities, including study
design, project monitoring, data management, and biostatistics.

PAREXEL's early phase services provide fully integrated solutions from First
in Man through Proof of Concept and help biopharmaceutical companies generate
better and faster go/no-go decisions about their compounds, and strive to
return solid, reproducible outcomes to succeed in later-phase trials.
PAREXEL's early phase capabilities include a full scope of early phase
studies, specialized trial design, state-of-the-art technologies,
hospital-based resources, and scientific expertise as well as vast experience
in the neurology, cardiology, respiratory, and metabolism/endocrine
therapeutic areas. With early phase unit locations across three continents,
PAREXEL provides rapid study start-up and access to diverse patient
populations in addition to healthy volunteers. For more information about
PAREXEL's early phase capabilities visit:
http://www.PAREXEL.com/Early_Phase.html.

Mortara, which is distinguished in the field of non-invasive diagnostic
cardiology systems, has a long-standing relationship with the U.S. Food and
Drug Administration (FDA), providing ECG algorithm tools and data warehousing
solutions to support regulatory review of cardiac safety data. Since 2006, FDA
has been using Mortara's ECG Warehouse and toolset to review thorough QT
studies. Mortara Instrument manufactures and distributes its ECG devices and
related technology worldwide. The company's website is www.mortara.com.

About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical
services organization, providing a broad range of knowledge-based contract
research, medical communications and consulting services to the worldwide
pharmaceutical, biotechnology and medical device industries. Committed to
providing solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development and
commercialization continuum, from drug development and regulatory consulting
to clinical pharmacology, clinical trials management, medical education and
reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides
advanced technology solutions, including medical imaging, to facilitate the
clinical development process. Headquartered near Boston, Massachusetts,
PAREXEL operates in 70 locations throughout 52 countries around the world, and
has more than 9,130 employees. For more information about PAREXEL
International visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results
and events. For this purpose, any statements contained herein that are not
statements of historical fact may be deemed forward-looking statements.
Without limiting the foregoing, the words "believes," "anticipates," "plans,"
"expects," "intends," "appears," "estimates," "projects," "targets," and
similar expressions are also intended to identify forward-looking statements.
The forward-looking statements in this release involve a number of risks and
uncertainties. The Company's actual future results may differ significantly
from the results discussed in the forward-looking statements contained in this
release. Important factors that might cause such a difference include, but are
not limited to, risks associated with: actual operating performance; actual
expense savings and other operating improvements resulting from recent
restructurings; the loss, modification, or delay of contracts which would,
among other things, adversely impact the Company's recognition of revenue
included in backlog; the Company's dependence on certain industries and
clients; the Company's ability to win new business, manage growth and costs,
and attract and retain employees; the Company's ability to complete additional
acquisitions and to integrate newly acquired businesses or enter into new
lines of business, including, but not limited to, the successful business
integration and anticipated synergy achievements in connection with the
ClinPhone acquisition; the impact on the Company's business of government
regulation of the drug, medical device and biotechnology industry;
consolidation within the pharmaceutical industry and competition within the
biopharmaceutical services industry; the potential for significant liability
to clients and third parties; the potential adverse impact of health care
reform; and the effects of exchange rate fluctuations and other international
economic, political, and other risks. Such factors and others are discussed
more fully in the section entitled "Risk Factors" of the Company's Quarterly
Report on form 10-Q for the quarter ended September 30, 2009 as filed with the
SEC on November 6, 2009, which "Risk Factors" discussion is incorporated by
reference in this press release. The forward-looking statements included in
this press release represent the Company's estimates as of the date of this
release. The Company specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking statements
should not be relied upon as representing the Company's estimates or views as
of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and
Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All
other names or marks may be registered trademarks or trademarks of PAREXEL
International Corporation, Perceptive Informatics, Inc. or their respective
owners and are hereby acknowledged.

Contacts:
Jennifer Baird, Senior Director of Public Relations
PAREXEL International
Tel: +781-434-4409
Email: Jennifer.Baird@PAREXEL.com

Gene Carozza/Kim Baker
PAN Communications
Tel: +978-474-1900
Email: PAREXEL@pancomm.com

SOURCE PAREXEL International Corporation

Jennifer Baird, Senior Director of Public Relations of PAREXEL International,
+1-781-434-4409, Jennifer.Baird@PAREXEL.com; or Gene Carozza or Kim Baker,
both at +1-978-474-1900, PAREXEL@pancomm.com, both of PAN Communications